SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or the "Company") (NASDAQ:OVID). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or the "Company") (NASDAQ:OVID). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Investors who lost money on Ovid Therapeutics Inc. should contact Levi & Korsinsky about an ongoing investigation - OVID
NEW YORK, NY / ACCESSWIRE / June 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ovid Therapeutics Inc. ("Ovid") (NASDAQ:OVID) concerning possible violations of federal securities laws. To obtain additional information, go to: Click Here or contact Joseph E.
OVID ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on your Ovid Therapeutics Inc. Investment
NEW YORK, NY / ACCESSWIRE / June 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ovid Therapeutics Inc. ("Ovid") (NASDAQ:OVID) concerning possible violations of federal securities laws. To obtain additional information, go to: Click Here or contact Joseph E.
Lost Money on Ovid Therapeutics Inc.(OVID)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ovid Therapeutics Inc. ("Ovid") (NASDAQ:OVID) concerning possible violations of federal securities laws. To obtain additional information, go to: Click Here or contact Joseph E.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or the "Company") (NASDAQ:OVID). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
Two late-stage studies, which evaluated Ovid Therapeutics' (OVID) experimental drug for two forms of epilepsy, fail to meet their primary endpoints.
Why Is Ovid Therapeutics (OVID) Stock Down 69% Today?
Ovid Therapeutics (NASDAQ: OVID ) stock is falling hard on Monday after the company announced results from a Phase 3 clinical trial conducted by Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited announced the results of its trial of soticlestat as a treatment for Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).
Ovid Therapeutics Inc. (NASDAQ:OVID) Expected to Earn Q2 2024 Earnings of ($0.25) Per Share
Ovid Therapeutics Inc. (NASDAQ:OVID – Free Report) – Investment analysts at HC Wainwright lowered their Q2 2024 earnings per share estimates for Ovid Therapeutics in a research report issued to clients and investors on Thursday, May 16th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.25) per share for the quarter, down from their previous forecast of ($0.24). HC Wainwright currently has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.85) per share. HC Wainwright also issued estimates for Ovid Therapeutics’ Q3 2024 earnings at ($0.26) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.72) EPS, Q2 2025 earnings at ($0.23) EPS and FY2025 earnings at ($0.61) EPS. OVID has been the subject of several other reports. Citigroup reduced their price target on Ovid Therapeutics from $4.00 to $3.50 and set a “neutral” rating for the company in a research report on Tuesday, May 7th. B. Riley started coverage on Ovid Therapeutics in a research report on Tuesday, April 30th. They issued a “buy” rating and a $9.00 price target for the company. Finally, Wedbush started coverage on Ovid Therapeutics in a research report on Friday, April 5th. They issued an “outperform” rating and a $8.00 price target for the company. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, Ovid Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $8.08. Check Out Our Latest Research Report on Ovid Therapeutics Ovid Therapeutics Price Performance Shares of NASDAQ OVID opened at $3.15 on Monday. The stock has a market cap of $223.48 million, a PE ratio of -4.32 and a beta of 0.69. Ovid Therapeutics has a fifty-two week low of $2.57 and a fifty-two week high of $4.14. The company has a debt-to-equity ratio of 0.18, a quick ratio of 9.55 and a current ratio of 10.47. The stock has a fifty day moving average of $3.07 and a 200-day moving average of $3.29. Ovid Therapeutics (NASDAQ:OVID – Get Free Report) last issued its earnings results on Friday, March 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.05). The firm had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.10 million. Ovid Therapeutics had a negative net margin of 10,691.14% and a negative return on equity of 53.62%. Insider Buying and Selling In other Ovid Therapeutics news, CEO Jeremy M. Levin bought 18,248 shares of Ovid Therapeutics stock in a transaction that occurred on Monday, March 18th. The stock was acquired at an average cost of $2.76 per share, for a total transaction of $50,364.48. Following the completion of the transaction, the chief executive officer now directly owns 3,616,715 shares in the company, valued at $9,982,133.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 13.30% of the stock is owned by company insiders. Institutional Investors Weigh In On Ovid Therapeutics A number of hedge funds and other institutional investors have recently modified their holdings of OVID. Price T Rowe Associates Inc. MD raised its position in Ovid Therapeutics by 22.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 17,396 shares of the company’s stock valued at $54,000 after purchasing an additional 3,145 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Ovid Therapeutics by 66.0% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 13,579 shares of the company’s stock valued at $41,000 after purchasing an additional 5,401 shares during the last quarter. Empowered Funds LLC raised its position in Ovid Therapeutics by 8.1% during the 1st quarter. Empowered Funds LLC now owns 128,070 shares of the company’s stock valued at $391,000 after purchasing an additional 9,625 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in Ovid Therapeutics by 17.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 81,173 shares of the company’s stock valued at $312,000 after purchasing an additional 11,926 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in shares of Ovid Therapeutics by 52.7% in the 4th quarter. SG Americas Securities LLC now owns 39,792 shares of the company’s stock worth $128,000 after acquiring an additional 13,728 shares in the last quarter. Institutional investors own 72.24% of the company’s stock. Ovid Therapeutics Company Profile (Get Free Report) Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. Read More Five stocks we like better than Ovid Therapeutics What is a buyback in stocks? A comprehensive guide for investors MarketBeat Week in Review – 5/13 – 5/17 Natural Gas Prices Continue To Rally, These Stocks Should Benefit Take-Two Interactive Software Offers 2nd Chance for Investors Using the MarketBeat Dividend Tax Calculator Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
